XFOR ▲ +0.6% - X4 Pharmaceuticals, Inc.
$XFOR - X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day
29-OCT-2026 04:30 PM ET
Share this post
More filings for $XFOR
XFOR ▲ +6.1% - X4 Pharmaceuticals, Inc.Oct 9, 2026XFOR ▼ -0.7% - X4 Pharmaceuticals, Inc.Oct 8, 2026XFOR - X4 Pharmaceuticals, Inc. - SEC Filing Update (07-OCT-2026) | ThinkSabio - Stocks SimplifiedOct 7, 2026XFOR ▼ -2.4% - X4 Pharmaceuticals, Inc.Oct 1, 2026XFOR - X4 Pharmaceuticals, Inc. - SEC Filing Update (21-SEP-2026) | ThinkSabio - Stocks SimplifiedSep 22, 2026XFOR ▲ +2.9% - X4 Pharmaceuticals, Inc.Sep 9, 2026
View full $XFOR filing history →💬 Comments
Loading comments…
Leave a comment